Additionally, miR-378 promotes cell survival, tumour growth and angiogenesis by targeting TUSC2 and miR-378/TUSC2 levels predict adverse prognosis in acute myeloid leukaemia patients [36,37]. The gene discussed is TUSC2; the disease is neoplasm.